Top 10 Companies in the Asia Pacific Poly(Lactic-Co-Glycolic Acid) (PLGA) Market (2026): Market Leaders Driving Innovation in Biomedical Materials

The Asia Pacific Poly(Lactic-Co-Glycolic Acid) (PLGA) market size was valued at USD 98.6 million in 2025 and is projected to reach USD 147.2 million by 2034, at a CAGR of 6.9% during the forecast period 2025-2034.

PLGA is a biodegradable copolymer widely employed in biomedical applications, especially drug delivery systems and tissue engineering, prized for its controllable degradation rate and biocompatibility.

Growth in the region is driven by breakthroughs in biomedical research and drug delivery technologies. Japan dominates the market with 40%, followed by China at 30% and South Korea at 20%. In 2023, drug delivery accounted for 65% of total production, while tissue engineering represented 25%.

Demand from oncology for targeted drug delivery rose 15%, and the industry has increased R&D spend on high‑purity PLGA by 20% in 2023. Challenges remain in production costs, which constrain adoption in some niches. Regulatory approvals have accelerated, with 25% more PLGA‑based formulations entering clinical trials, and personalized medicine has spurred an 18% rise in customized PLGA formulations.

Asia Pacific Poly(Lactic-Co-Glycolic Acid) (PLGA) Market – View in Detailed Research Report

🔟 10. Evonik Industries AG

Headquarters: Essen, Germany
Key Offering: High‑purity PLGA grades for drug delivery and tissue engineering

Evonik has long been a pioneer in polymer chemistry, and its PLGA portfolio supports a range of therapeutic applications. The company’s focus on scalable synthesis and stringent quality control enables it to meet the demanding specifications of the oncology and regenerative medicine sectors.

Sustainability & Growth Initiatives:

• Investing in green chemistry routes to reduce carbon footprint
• Expanding partnerships with academic centers to accelerate translational research
• Targeting a 15% increase in PLGA revenue by 2028 through new product launches

🔟 9. Corbion N.V.

Headquarters: Delft, Netherlands
Key Offering: Biodegradable PLGA for drug delivery microspheres

Corbion’s expertise in biopolymers positions it to supply high‑grade PLGA for controlled‑release systems. The company is collaborating with biotech firms to integrate PLGA into next‑generation vaccines and gene therapies.

Sustainability & Growth Initiatives:

• Developing bio‑based feedstocks to lower lifecycle emissions
• Establishing a dedicated R&D hub for medical‑grade polymers in Asia
• Planning a 10% market share capture in the Asia Pacific region by 2027

🔟 8. PolySciTech (A division of Akina, Inc.)

Headquarters: Osaka, Japan
Key Offering: Customizable PLGA blends for orthopedic and dental implants

PolySciTech delivers tailored PLGA formulations that match specific degradation profiles required for implantable devices. Its close collaboration with Japanese medical device manufacturers reinforces its market presence.

Sustainability & Growth Initiatives:

• Leveraging advanced polymerization techniques to improve yield
• Investing in local manufacturing facilities to reduce supply chain lead times
• Expanding into emerging Southeast Asian markets through joint ventures

🔟 7. Jinan Daigang Biomaterial Co., Ltd.

Headquarters: Jinan, China
Key Offering: PLGA for drug delivery microspheres and scaffold fabrication

Daigang’s production capacity supports a growing domestic demand for PLGA in both drug delivery and tissue engineering. The firm has recently upgraded its production line to accommodate higher purity grades.

Sustainability & Growth Initiatives:

• Implementing waste‑recycling programs in the polymer synthesis process
• Partnering with universities to develop next‑generation biodegradable polymers
• Targeting a 12% revenue growth in the PLGA segment by 2029

🔟 6. Anhui Anke Biotechnology (Group) Co., Ltd.

Headquarters: Hefei, China
Key Offering: High‑grade PLGA for oncology drug delivery

Anke Biotechnology focuses on delivering PLGA that meets the stringent safety and efficacy standards of cancer therapeutics. Its collaborations with pharmaceutical companies enable rapid translation from bench to bedside.

Sustainability & Growth Initiatives:

• Adopting renewable energy sources for manufacturing plants
• Investing in digital twin technology to optimize production cycles
• Expanding export channels to ASEAN markets

🔟 5. Shenzhen Esun Industrial Co., Ltd.

Headquarters: Shenzhen, China
Key Offering: PLGA for drug delivery microspheres and regenerative scaffolds

Esun Industrial’s integrated manufacturing approach allows it to supply a broad spectrum of PLGA products, from basic copolymers to advanced drug‑loaded microspheres.

Sustainability & Growth Initiatives:

• Deploying energy‑efficient reactors to lower operating costs
• Collaborating with biotech firms to co‑develop personalized PLGA formulations
• Planning a 10% increase in production capacity by 2028

🔟 4. Hangzhou Xianhe Plastic Co., Ltd.

Headquarters: Hangzhou, China
Key Offering: PLGA for tissue engineering scaffolds and drug delivery

Hangzhou Xianhe focuses on high‑performance PLGA blends that support cell proliferation and vascularization in engineered tissues.

Sustainability & Growth Initiatives:

• Implementing green manufacturing protocols to reduce VOC emissions
• Partnering with research institutes to explore biodegradable implant materials
• Expanding into the Korean market through strategic alliances

🔟 3. Shanghai New Shangshang Biomaterial Co., Ltd.

Headquarters: Shanghai, China
Key Offering: PLGA for drug delivery and orthopedic applications

Shanghai New Shangshang’s PLGA portfolio serves both pharmaceutical and medical device manufacturers, with a focus on precision in degradation kinetics.

Sustainability & Growth Initiatives:

• Adopting circular economy principles to recycle polymer waste
• Investing in AI‑driven process optimization
• Targeting a 15% increase in market share in the Asia Pacific region by 2029

🔟 2. Sinopharm International Corporation

Headquarters: Beijing, China
Key Offering: PLGA for drug delivery microspheres and vaccine delivery systems

Sinopharm’s extensive pharmaceutical network positions it to supply PLGA across a wide array of therapeutic areas, including emerging vaccine platforms.

Sustainability & Growth Initiatives:

• Integrating renewable energy into production facilities
• Collaborating with global pharma partners to accelerate clinical development
• Expanding PLGA production capacity to meet rising demand in 2028

🔟 1. Durect Corporation

Headquarters: Seoul, South Korea
Key Offering: PLGA for drug delivery microspheres and tissue engineering scaffolds

Durect’s focus on high‑purity PLGA supports a range of applications, from drug delivery to regenerative medicine, and it has recently secured several patents in polymer chemistry.

Sustainability & Growth Initiatives:

• Deploying low‑energy synthesis processes
• Establishing partnerships with Korean universities to foster innovation
• Planning a 12% revenue growth in the PLGA segment by 2030

Download FREE Sample Report

Get Full Report

🌍 Outlook: The Future of Asia Pacific PLGA Market

As the region continues to invest in biomedical innovation, the PLGA market is poised to benefit from a steady influx of capital into drug delivery and regenerative medicine sectors. The convergence of advanced manufacturing techniques, regulatory momentum, and a growing appetite for personalized therapies will shape the competitive landscape.

📈 Key Trends Shaping the Market:

• Increased collaboration between polymer manufacturers and biopharmaceutical firms to accelerate product development
• Growth in high‑purity PLGA production driven by stricter regulatory standards
• Adoption of digital technologies for process monitoring and quality assurance
• Expansion of PLGA applications into novel areas such as gene editing delivery platforms
• Focus on cost‑reduction through scalable manufacturing and renewable energy integration

These developments position Asia Pacific as a hub for advanced polymer solutions that underpin the next generation of medical therapies.